Meningococcal vaccine trial for ages 2 to 59
Part of Brain & nervous system, Infections clinical trials.
This trial tests a new vaccine that helps protect against 6 types of meningococcal bacteria, which can cause serious infections like meningitis. It is for healthy people aged 2 to 59 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 59 years old.
- You need to be in good general health.
- You or your legal guardian must understand and sign a consent form.
- You must be willing to follow the study schedule and stay in contact.
- You must not have had a meningococcal vaccine (for children 2-6) or a past serious reaction to vaccines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new vaccine safely protects infants aged 6 to 11 months against four types of meningococcal bacteria that can cause serious infections like meningitis and blood infections. It is designed for healthy babies who have not yet received any meningococcal vaccine.
This trial tests a vaccine that protects against four types of meningococcal bacteria (groups A, C, W, and Y) in healthy babies aged 3 to 5 months. The vaccine is given to help prevent meningitis and other serious infections.
This study tests a vaccine that protects against four common types of meningitis (groups A, C, Y, and W135) in toddlers aged 12–23 months. It helps researchers see if the vaccine is safe and works well for young children.
This trial tests a new meningococcal conjugate vaccine (EG-MCV4) in healthy adults to see how well the body's immune system responds and if it's safe. If you qualify, you'd help researchers learn if this vaccine can prevent meningococcal disease.
This study tests an experimental meningitis vaccine in healthy babies and toddlers to see how well it works and if it's safe. If your child is between 2 and 23 months old and in good health, they might be able to join.
This trial tests a new meningitis vaccine (GNG-DE) to see how well it works compared to a vaccine already on the market. It might help protect you or your child from meningococcal disease.
Hear when a new Meningococcal Meningitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.